3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
pembrolizumab
49
Carboplatin
44
Magnetic Resonance Spectroscopy
40
Specimen Handling
39
Pemetrexed
34
Cisplatin
25
Blood Specimen Collection
25
durvalumab
17
Paclitaxel
16
osimertinib
15
Radiotherapy
15
Radiosurgery
15
Bevacizumab
15
Gemcitabine
14
atezolizumab
13
Nivolumab
13
Biopsy
13
Drug Therapy
12
Standard of Care
10
Practice Guidelines as Topic
10
Immunoglobulin G
10
Docetaxel
10
130-nm albumin-bound paclitaxel
10
X-Rays
9
Taxes
9
Educational Status
9
Disulfides
9
tislelizumab
8
Etoposide
8
Cetuximab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lung Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled